Shopping Cart
Remove All
Your shopping cart is currently empty
Blosozumab (Synonyms: TST-002, TST002, LY-2541546, LY2541546)
Catalog No. T78278 Copy Product Info
🥰Excellent
Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway.
Blosozumab
Copy Product Info🥰Excellent
Catalog No. T78278
Synonyms TST-002, TST002, LY-2541546, LY2541546
Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway.
Blosozumab
Cas No. 1132758-87-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock | |
| 5 mg | $629 | - | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.53% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Blosozumab (LY2541546) is a humanized monoclonal antibody targeting sclerostin, promoting bone formation and inhibiting bone resorption, used in osteoporosis research. Blosozumab increases bone mass by neutralizing the negative effects of sclerostin on the Wnt signaling pathway. |
| In vivo | Blosozumab is a humanized monoclonal antibody (IgG4) that has been optimized for neutralizing the sclerosing protein. In 5 - and 6-month non-clinical safety studies in rats, Blosozumab resulted in a dose-dependent, reversible reduction in platelet counts, accompanied by accelerated platelet production, increased megakaryocyte growth, and altered megakaryocyte morphology. There was no change in platelet counts or megakaryocytes in cynomophagus monkeys treated with Blosozumab. [1] |
| Synonyms | TST-002, TST002, LY-2541546, LY2541546 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | SOST/Sclerostin |
| Molecular Weight | 144.88 kDa |
| Cas No. | 1132758-87-2 |
| Isotype | Human IgG4SP kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Blosozumab | purchase Blosozumab | Blosozumab cost | order Blosozumab | Blosozumab in vivo | Blosozumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.